Skip to content

Source filing unavailable

Q2 2020 · —
Revenue—
Net Income$2.26Mno prior Q2 2019 on fileN/M vs Q1 2020
EPS Diluted$0.22no prior Q2 2019 on fileN/M vs Q1 2020
Operating Income-$5,065,000—
Operating Cash Flowderived-$4,295,000—
Free Cash Flowderived-$4,340,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q2 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR